Document is current

Documents that mention this clinical trial

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
https://doi.org/10.1136/jitc-2021-002742

Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540

Dysregulation of CD4⁺and CD8⁺resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis
https://doi.org/10.1136/jitc-2023-008628

Managing IBD in patients with previous cancers
https://doi.org/10.1136/flgastro-2022-102187

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
https://doi.org/10.1136/jitc-2021-002850

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
https://doi.org/10.1136/jitc-2021-003277

Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.
https://doi.org/10.1200/jco.2024.42.16_suppl.2661

Documents that mention this clinical trial

Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540

Documents that mention this clinical trial

Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540

Documents that mention this clinical trial

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
https://doi.org/10.1136/jitc-2021-002435

Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
https://doi.org/10.1136/jitc-2020-002252

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-001884

Corticosteroid-resistant immune-related adverse events: a systematic review
https://doi.org/10.1136/jitc-2023-007409

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
https://doi.org/10.1136/jitc-2020-001731

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
https://doi.org/10.1136/jitc-2022-004670

Documents that mention this clinical trial

Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps2680

696 Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): a phase 3, investigator-initiated, randomized, double blind, placebo-controlled trial
https://doi.org/10.1136/jitc-2022-sitc2022.0696

Cardiovascular toxicity of immune therapies for cancer
https://doi.org/10.1136/bmj-2023-075859

Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540

Clinical Characteristics and Mechanisms of Acute Myocarditis
https://doi.org/10.1161/circresaha.124.324674

Evaluation and management of chest pain from cardiovascular causes in female patients
https://doi.org/10.1136/bmj-2025-086177

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776